Category: MS Drug Therapies

Rituximab More Effective Than Gilenya, Tecfidera, and Comparable to Tysabri, Study Finds

AUGUST 11, 2020   BY MARTA FIGUEIREDO   Rituximab is more effective and leads to fewer treatment discontinuations in people with multiple sclerosis (MS) than Gilenya (fingolimod) and Tecfidera (dimethyl…

Stuart Schlossman

Jeffrey Cohen, MD: S1P Modulator Development in Multiple Sclerosis

Click HERE to Subscribe for the MS Beacon Newsletter “The hope was that by developing more selective S1P modulators, that…

Stuart Schlossman

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

August 5, 2020                 Drug Shows Promise in Preventing Multiple Sclerosis Relapses Ofatumumab is…

Stuart Schlossman

Innovations in MS Care and Treatment

Click HERE to Subscribe for the MS Beacon Newsletter Event Date: October 12, 2019 { a (3) Speaker presentation and…

Stuart Schlossman

Novartis update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Basel, June 2, 2020 —  Novartis today announced that it has received notice from the US Food and Drug Administration (FDA)…

Stuart Schlossman

Drugs in Development for MS, Including Ofatumumab (with MS Neurology experts Lublin; Bar-Or; Calabresi; Coyle and Krieger)

This NeurologyLive Peer Exchange, “Advances in Early Treatment Approaches in Multiple Sclerosis,” includes insight from Fred D. Lublin, MD; Amit Bar-Or, MD, FRCP;…

Stuart Schlossman

Response to Cladribine Tablets in RRMS

Click HERE to Subscribe for the MS Beacon Newsletter ““““““““““““““ Jeffrey M. Kaplan, MD, and Matthew J. Baker, MD, discuss…

Stuart Schlossman

Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

Jul 02, 2020 — Mark Freedman, MD, outlines a retrospective trial presented at the Consortium of Multiple Sclerosis Centers (CMSC)…

Stuart Schlossman

Short-Commitment Dosing Regimen Gives Cladribine An Advantage in MS

Click HERE to Subscribe for the MS Beacon Newsletter The professor of clinical neurology, and director of the MS Division…

Stuart Schlossman

NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS

If you think you have been exposed to COVID‑19 and develop a fever and symptoms, such as cough or difficulty…

Stuart Schlossman

Categories

Latest Blog Posts